Camrelizumab with or without Autologous Cytokine-induced Killer Cell Therapy in Patients with Refractory Clear Cell Renal Cell Carcinoma: A Randomized Pilot Study
Shuzhan Li(Tianjin Medical University Cancer Institute and Hospital), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Wenwen Yu(Tianjin Medical University Cancer Institute and Hospital), Weijiao Du(Tianjin Medical University Cancer Institute and Hospital), Yanjuan Xiong(Tianjin Medical University Cancer Institute and Hospital), Runmei Li(Tianjin Medical University Cancer Institute and Hospital), Zhenzhen Hui(Tianjin Medical University Cancer Institute and Hospital), Fan Yang(Gannan Medical University), Yang Wang(Tianjin Medical University Cancer Institute and Hospital), Li Zhou(Peking University), Qian Sun(Tianjin Medical University Cancer Institute and Hospital), Xinwei Zhang(Weifang Medical University), Liang Liu(Dongyang University), Jiali Zhang(Wuhan University), Tian Xiao(Yunnan University of Traditional Chinese Medicine), Ying Han(Fujian University of Traditional Chinese Medicine), Meng Shen(Tianjin Medical University Cancer Institute and Hospital), Hua Zhao, Baozhu Ren(Tianjin Medical University Cancer Institute and Hospital), Jing Qin(Hong Kong Polytechnic University), Weihong Zhang(Tianjin Medical University Cancer Institute and Hospital), Shui Cao(Tianjin Medical University Cancer Institute and Hospital)
Cited by 0
Related Papers
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma
|BMC Cancer|2012|166
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
|Nature Communications|2021|151